Author

S. Morsli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:fluorescence / live-cell microscopy· 1 Organism:mouse· 1 Organism:zebrafish· 1

Frequent Co-Authors

C. A. Loynes· 1 shared C. Henriques· 1 shared C. Martins· 1 shared D. M. Rassl· 1 shared D. Macias· 1 shared D. Munoz-Espin· 1 shared D. Veroutis· 1 shared E. Gonzalez-Gualda· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

C. A. Loynes

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A p21-GFP zebrafish model of senescence for rapid testing of senolytics in vivo.

S. Morsli, C. Henriques, P. s. Ellis, H. J. Mortiboys, S. Baxendale, C. A. Loynes, S. Renshaw, I. Bellantuono

This paper develops a zebrafish model expressing p21-GFP to study senescence and test senolytics, showing that quercetin and dasatinib reduce senescent cells in a 5-day assay.

bioRxiv · Sep 19, 2022Pharmacology & Toxicology

A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer

E. Gonzalez-Gualda, D. Macias, S. Morsli, E. Martin, H.-L. Ou, M. Denholm, I. Olan, R. Hoffmann, M. Dane, D. Veroutis, G. Medrano, F. Mulero, C. Martins, M. Barbacid, V. Gorgoulis, , D. Munoz-Espin

This study shows platinum chemotherapy induces a senescent secretome in lung cancer that promotes tumor growth via the TGFβR1/Akt-mTOR axis, and targeting this pathway reduces tumor burden.

bioRxiv · Aug 1, 2022 · PreprintCancer Biology